GRK2 mediates the phosphorylation of activated G protein‐coupled receptors (GPCRs), a process that triggers receptor desensitisation and internalisation, ultimately altering intracellular ...

“ATR-258, a synthetic small molecule, has favourable pharmacokinetics and in Phase 1 clinical trials has been administered just once a day as a capsule, making it a straightforward, patient-friendly ...

Figure 1, published in Cell. Discovery of adrenergic receptor agonists that increase glucose uptake with low cAMP generationNovel drug candidate ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Review the current valuation for Structure Therapeutics Inc ADR (GPCR:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Advertising Feature: Application Note Published: April 2008 Selecting a cyclic AMP kit for assaying GPCR target activation Jean-Luc Tardieu Nature Methods 5, iii–iv (2008) Cite this article ...

AbbVie and Sosei Heptares will initially focus on developing up to three GPCR-modulating small-molecule drugs to the point at which they are ready to start clinical trials in humans, whereupon ...

View the latest Structure Therapeutics Inc. ADR (GPCR) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Dr Fiona Marshall joins MSD from Sosei from Heptares, the UK biotech company she co-founded more than a decade ago, and which was acquired by Sosei in 2015.

In cardiovascular system, GPCRs can lead to hypertrophy, apoptosis, contraction, and cardiomyocytes survival. Some of the GPCR targeted therapeutics are used in clinic for treatment of heart failure ...